Last reviewed · How we verify
Immune Checkpoint Inhibitors
Immune checkpoint inhibitors block inhibitory signals on T cells, allowing the immune system to recognize and attack cancer cells.
Immune checkpoint inhibitors block inhibitory signals on T cells, allowing the immune system to recognize and attack cancer cells. Used for Various solid tumors and hematologic malignancies (specific indications depend on the particular checkpoint inhibitor agent).
At a glance
| Generic name | Immune Checkpoint Inhibitors |
|---|---|
| Also known as | Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, Toripalimab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab |
| Sponsor | The Central Hospital of Lishui City |
| Drug class | Immune checkpoint inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
These drugs work by inhibiting checkpoint proteins (such as PD-1, PD-L1, or CTLA-4) that cancer cells use to evade immune detection. By removing these 'brakes' on the immune system, checkpoint inhibitors restore T cell activation and proliferation, enabling enhanced anti-tumor immunity. This mechanism has proven effective across multiple cancer types.
Approved indications
- Various solid tumors and hematologic malignancies (specific indications depend on the particular checkpoint inhibitor agent)
Common side effects
- Fatigue
- Diarrhea
- Rash
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Hypothyroidism
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) (PHASE2)
- A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection (PHASE1, PHASE2)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
- Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (PHASE3)
- Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immune Checkpoint Inhibitors CI brief — competitive landscape report
- Immune Checkpoint Inhibitors updates RSS · CI watch RSS
- The Central Hospital of Lishui City portfolio CI